Immunome (IMNM) Research & Development (2019 - 2026)

Immunome (IMNM) has 8 years of Research & Development data on file, last reported at $46.4 million in Q1 2026.

• Quarterly Research & Development rose 25.79% year-over-year to $46.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.8 million (up 23.67% YoY) and the FY2025 annual result came in at $177.3 million, up 36.86% from the prior year.
• Research & Development slipped to $46.4 million in Q1 2026, from $50.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $50.8 million in Q4 2025 to a low of $3.8 million in Q3 2023.
• A 5-year average of $23.5 million and a median of $15.4 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development sank 51.56% — and 2024, when it surged 873.06%.
• Tracing IMNM's Research & Development over 5 years: stood at $4.3 million in 2022, then jumped by 126.65% to $9.6 million in 2023, then surged by 396.94% to $47.9 million in 2024, then climbed by 6.01% to $50.8 million in 2025, then declined by 8.64% to $46.4 million in 2026.
• The last three Research & Development figures came in at $46.4 million (Q1 2026), $50.8 million (Q4 2025), and $49.2 million (Q3 2025), per Business Quant data.